To evaluate the efficacy and safety of Apatinib in patients with metastatic colorectal cancer refractory to standard therapies

Trial Profile

To evaluate the efficacy and safety of Apatinib in patients with metastatic colorectal cancer refractory to standard therapies

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Apatinib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jun 2017 New trial record
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top